REYKJAVIK, Iceland — December 31, 2025 — Leads & Copy —
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in biosimilar medicines, has announced a USD 100 million senior term loan facility with a two-year maturity. The funding aims to bolster Alvotech’s liquidity and support its R&D pipeline and global product launches through 2026.
GoldenTree Asset Management led the transaction. The loan bears an interest rate of 12.50%, payable monthly in cash. It replaces the company’s previously disclosed working capital facility (ABL) and provides Alvotech with access to the full USD 100 million throughout the term of the loan.
According to Alvotech, the financing underscores the long-term commitment of GoldenTree and their alignment with Alvotech’s strategy. The support will strengthen the company’s ability to execute its growth plans, invest in R&D, and deliver biosimilars to patients, said Robert Wessman, Chairman and CEO of Alvotech.
Alvotech says it remains focused on advancing its R&D pipeline, which includes 30 products in development. The company continues to expand its production capacity and strengthen its supply chain to support four new global product launches through 2026.
The company also announced in June 2025 the repricing of its existing facility to an interest rate of SOFR plus 6.0% per annum, equivalent to approximately 9.8% based on the 30-day average SOFR rate of ~3.8%
Alvotech recently announced the placing of USD 108 million senior unsecured convertible bonds due 2030. Together these transactions position the Company to maintain its leading position and investment into its biosimilar development pipeline.
Contact:
Media
Benedikt Stefansson, VP Investor Relations and Global Communications
Sarah Macleod, Head of Global Communications
alvotech.media@alvotech.com
Investor Relations
Balaji Prasad, Chief Strategy Officer
Patrik Ling, VP Investor Relations Scandinavia (SE)
Benedikt Stefansson, VP Investor Relations and Global Communications (IS)
alvotech.ir@alvotech.com
Source: Alvotech
